Search

Your search keyword '"Lev-Tov H"' showing total 5 results
Start Over Author "Lev-Tov H" Topic dermatologic agents
5 results on '"Lev-Tov H"'

1. Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic.

Author

Sanchez DP, Kirsner RS, and Lev-Tov H

Subjects
Biological Products adverse effects, Biological Products standards, COVID-19, Coronavirus Infections epidemiology, Coronavirus Infections immunology, Dermatologic Agents standards, Dermatology methods, Dermatology standards, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents standards, Incidence, Meta-Analysis as Topic, Placebos adverse effects, Pneumonia, Viral epidemiology, Pneumonia, Viral immunology, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Respiratory Tract Infections chemically induced, Respiratory Tract Infections immunology, SARS-CoV-2, Skin Diseases immunology, Systematic Reviews as Topic, Betacoronavirus immunology, Coronavirus Infections prevention & control, Dermatologic Agents adverse effects, Pandemics prevention & control, Pneumonia, Viral prevention & control, Respiratory Tract Infections epidemiology, Skin Diseases drug therapy
Published
2020
Full Text
View/download PDF

2. Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis.

Author

Fowler E, Rosen J, Lev-Tov H, and Yosipovitch G

Subjects
Adult, Anus Neoplasms diagnosis, Anus Neoplasms immunology, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell immunology, Dermatitis, Atopic diagnosis, Dermatitis, Atopic immunology, Female, Humans, Male, Melanoma diagnosis, Melanoma immunology, Skin Neoplasms diagnosis, Skin Neoplasms immunology, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Anus Neoplasms therapy, Carcinoma, Squamous Cell therapy, Dermatitis, Atopic drug therapy, Dermatologic Agents therapeutic use, Immunosuppressive Agents therapeutic use, Melanoma therapy, Skin Neoplasms therapy
Published
2019
Full Text
View/download PDF

3. Trends in utilization of topical medications for treatment of rosacea in the United States (2005-2014): A cohort analysis.

Author

Lev-Tov H, Rill JS, Liu G, and Kirby JS

Subjects
Administration, Cutaneous, Adult, Anti-Bacterial Agents administration & dosage, Cohort Studies, Dermatologic Agents administration & dosage, Dicarboxylic Acids administration & dosage, Drug Costs statistics & numerical data, Drug Therapy, Combination, Drugs, Generic economics, Female, Humans, Male, Metronidazole administration & dosage, Middle Aged, Retrospective Studies, United States, Anti-Bacterial Agents therapeutic use, Dermatologic Agents therapeutic use, Dicarboxylic Acids therapeutic use, Drug Utilization trends, Metronidazole therapeutic use, Rosacea drug therapy, Rosacea economics
Published
2019
Full Text
View/download PDF

4. Fifteen Minute Test May Save 15% or More on Rosacea Treatment.

Author

Darwin E, Cervantes J, and Lev-Tov H

Subjects
Adrenergic alpha-Agonists administration & dosage, Adrenergic alpha-Agonists economics, Dermatologic Agents administration & dosage, Humans, Oxymetazoline administration & dosage, Oxymetazoline economics, Time Factors, Treatment Outcome, Dermatologic Agents economics, Rosacea drug therapy, Rosacea economics, Skin Tests economics, Skin Tests methods
Abstract

Rosacea is a common inflammatory skin condition that impacts a large portion of fair-skinned populations. The redness associated with rosacea can be a significant challenge. Brimonidine sulfate and oxymetazoline HCL were both recently approved by the FDA for the management of facial redness. These agents, however, are costly, and not all patients respond to the medication. Herein, we describe a clinical pearl that helps to optimize patient selection for the medications. This saves the patient and the health care system both time and money. J Drugs Dermatol. 2018;17(5):692-693.

Published
2018

5. Alefacept - a drug review.

Author

Lev-Tov H and Hadi S

Subjects
Alefacept, Clinical Trials as Topic, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Treatment Outcome, Dermatologic Agents therapeutic use, Psoriasis drug therapy, Recombinant Fusion Proteins therapeutic use
Abstract

Alefacept is an immunobiologic agent that has been recently introduced in the treatment of plaque psoriasis. The author presents a brief review of the drug, its efficacy and safety profile. Recent case reports of the use of alefacept in conjunction with other conditions as well as the drug's possible use for treatment of other conditions are reviewed as well.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results